MBX Biosciences has dosed the first patient in its pivotal Phase 3 oPTimize trial of a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The s

MBX Biosciences has dosed the first patient in its pivotal Phase 3 oPTimize trial of a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The study will test safety and efficacy in a rare disease with limited treatment options.